HC Wainwright Issues Negative Forecast for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - HC Wainwright dropped their Q2 2025 EPS estimates for shares of United Therapeutics in a report released on Monday, May 5th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $7.02 per share for the quarter, down from their previous forecast of $7.39. HC Wainwright currently has a "Buy" rating and a $425.00 price objective on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics' Q3 2025 earnings at $7.03 EPS and Q4 2025 earnings at $6.63 EPS.

Other equities analysts have also issued research reports about the company. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a research note on Monday, April 21st. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Morgan Stanley raised their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $392.00.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $6.58 during mid-day trading on Tuesday, hitting $301.42. 335,344 shares of the company's stock traded hands, compared to its average volume of 440,265. The company has a market capitalization of $13.60 billion, a P/E ratio of 13.24, a P/E/G ratio of 0.97 and a beta of 0.58. The company has a fifty day moving average of $300.53 and a 200 day moving average of $342.14. United Therapeutics has a twelve month low of $263.56 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter last year, the company earned $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 75,500 shares of company stock worth $24,245,880. Insiders own 11.90% of the company's stock.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at $25,000. Dunhill Financial LLC grew its position in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. Sound Income Strategies LLC acquired a new position in United Therapeutics in the first quarter valued at $49,000. State of Wyoming purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $62,000. Finally, Curat Global LLC purchased a new position in shares of United Therapeutics during the first quarter worth about $63,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.